pharma · Knee Osteoarthritis · Hypoplastic Left Heart Syndrome · RGBP
Regeneron Ireland Designated
Regeneron Ireland Designated Activity Company (DAC)
Regeneron Ireland Designated patent portfolio — 8292 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- LA MESA, CA, IE
- Programs
- 10
- Drugs
- 62
- Patents
- 8292
Regeneron Ireland Designated patents
8,292 pharmaceutical patents indexed for Regeneron Ireland Designated. 419 expire within 24 months.
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 419 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11702657
TRNA/pre-miRNA compositions and methods for treating hepatocellular carcinoma
granted -
US 11701433
Complexes for delivery of antigenic peptides
granted -
US 11702701
Means and methods for staging, typing and treating a cancerous disease
granted -
US 11701361
p110-delta inhibitors treat and prevent autoimmunity while sparing the ability to mount an immune response to exogenous immunogens
granted -
US 11702442
Cyclic dinucleotide compounds as sting agonists
granted -
US 11696933
HLA-restricted VCX/Y peptides and T cell receptors and use thereof
granted -
US 11696904
Prodrug for therapeutic applications
granted -
US 11699503
Methods of identifying and treating patient populations amenable to cancer immunotherapy
granted -
US 11696950
Dry solid aluminum adjuvant-containing vaccines and related methods thereof
granted -
US 11696929
Methods and systems for conserving highly expanded cells
granted -
US 11696898
Halogenated ether compounds and methods of inducing anesthesia
granted -
US 11690919
Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
granted -
US 11690850
Inhibitors of receptor interacting protein kinase I for the treatment of disease
granted -
US 11690837
Methods of improving cell-based therapy
granted -
US 11690825
20-HETE receptor (GPR75) antagonists and methods of use
granted -
US 11692176
Halogenation of complex organic compounds
granted -
US 11691989
Macrocyclic indoles as Mcl-1 inhibitors
granted -
US 11692027
Antibody and protein therapeutic formulations and uses thereof
granted -
US 11690851
Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer
granted -
US 11692229
Fast diagnosis and personalized treatments for acne
granted -
US 11692184
Thermostable RNA-guided endonucleases and methods of use thereof
granted -
US 11684626
Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
granted -
US 11685710
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
granted -
US 11685909
CRISPR-Cas effector polypeptides and methods of use thereof
granted -
US 11684638
Targeted delivery system, system components, and methods
granted -
US 11685775
Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody
granted -
US 11684585
Nanoscale coatings for encapsulation of biological entities
granted -
US 11684797
Laser assisted wound healing protocol and system
granted -
US 11684657
HLA-restricted VGLL1 peptides and use thereof in promoting an immune response in a subject
granted -
US 11684614
Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
granted -
US 11684609
Compounds and methods for treating an epileptic disorder
granted -
US 11680105
Antibody fragments for detecting cancer and methods of use
granted -
US 11679157
Controlled release mucoadhesive systems
granted -
US 11679093
2-naphthimidamides, analogues thereof, and methods of treatment using same
granted -
US 11679075
Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
granted -
US 11679113
Anticancer treatment for uveal melanoma
granted -
US 11680067
Small molecules for the treatment of primary cancer and cancer metastasis
granted -
US 11680244
Method for generating human dendritic cells for immunotherapy
granted -
US 11679103
Multi-targeting agents for Alzheimer's disease therapy
granted -
US 11680249
Adeno-associated virus capsid variants and methods of use thereof
granted -
US 11679100
Methods of enhancing immunity
granted -
US 11672832
Development of amnion-like tissue from human pluripotent stem cells
granted -
US 11673867
Sulfonamide derivative or pharmaceutically acceptable acid-addition salt
granted -
US 11673866
Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases
granted -
US 11674159
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 11674121
Platform for generating safe cell therapeutics
granted -
US 11673898
Substituted inhibitors of menin-MLL and methods of use
granted -
US 11673966
Monoclonal and humanized antibodies to a cancer glycopeptide
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
419 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.